Kazia Therapeutics
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Oncology
Kazia Therapeutics is a clinical-stage oncology company focused on high-need cancers of the central nervous system and select aggressive solid tumors. Our mission is to redefine cancer treatment by moving beyond conventional pathway inhibition toward therapeutic reprogramming of cancer biology by targeting regulatory drivers of growth, immune escape, and relapse to deliver more durable outcomes for patients.
Our portfolio includes two clinical-stage small-molecule programs: 1) paxalisib, a brain-penetrant dual inhibitor of the PI3K/AKT/mTOR pathway, a critical signaling route that helps cancer cells grow and multiply, licensed from Genentech, and 2) EVT801, a selective VEGFR3 inhibitor discovered by Sanofi and licensed from Evotec SE. Additionally, Kazia has an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a PD-L1 protein degrader platform, alongside worldwide rights to combination IP that covers pairing PI3K inhibitors with other cancer therapies.
Company HQ City:
Sydney
Company HQ State:
NSW
Company HQ Country:
Australia
Year Founded:
2016
Lead Product in Development:
Paxalisib - Advanced Breast Cancer (Phase 1), Glioblastoma (Phase 3), Childhood Brain Cancer (Phase 2/Preclinical)
CEO
Dr. John Friend
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
1
Exchange
Nasdaq
Ticker
KZIA
When you expect your next catalyst update?
Multiple dates in 2026
What is your next catalyst (value inflection) update?
Anticipated data readouts from multiple ongoing trials
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}